Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib dose-escalation in advanced hepatocellular carcinoma
NCT05622136Phase 2Active, not recruiting
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Sep 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in hepatocellular carcinoma (HCC), sponsored by Instituto do Câncer do Estado de São Paulo. Started Sep 2023; status: active, not recruiting.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05622136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622136.